What is Manual?
Manual operates as a comprehensive men's healthcare platform, specializing in the delivery of treatments for conditions such as hair loss, low testosterone, and erectile dysfunction. By integrating science-backed prescription therapies with ongoing medical support and at-home diagnostics, the company addresses critical gaps in traditional healthcare delivery. Its market position is defined by a commitment to convenience and personalization, effectively removing the friction often associated with seeking treatment for sensitive health issues. Through its digital-first approach, Manual is actively disrupting the conventional healthcare model, providing a streamlined, informative, and supportive experience for its user base.
How much funding has Manual raised?
Manual has raised a total of $33.5M across 2 funding rounds:
Angel/Seed
$3.5M
Series A
$30M
Angel/Seed (2019): $3.5M, investors not publicly disclosed
Series A (2021): $30M led by Felix Capital Partners LLP, Sonoma Brands, and Cherry Ventures
Key Investors in Manual
Sonoma Brands
Sonoma Brands Capital is a private equity firm that focuses on the growth sectors of the consumer economy, partnering with innovative founders to build enduring brands.
Cherry Ventures
Cherry Ventures is a venture capital firm based in Berlin, London, and Stockholm that focuses on early-stage investments in European startups, leveraging the experience of former entrepreneurs.
Felix Capital Partners LLP
Felix Capital is a London-based venture capital firm that invests in digital lifestyle businesses, focusing on the intersection of technology and creative consumer brands.
What's next for Manual?
With the recent influx of capital, Manual is poised to scale its operations and enhance its technological infrastructure to support a larger patient volume. The strategic focus will likely shift toward deepening its product portfolio and expanding its diagnostic capabilities, ensuring that the platform remains a leader in the men's wellness space. Furthermore, the company is expected to leverage its partnerships with key investors to optimize its supply chain and strengthen its brand presence in international markets. As it navigates this growth phase, the firm will continue to prioritize the integration of data-driven insights to provide more personalized care, ultimately aiming to set a new standard for digital health accessibility and patient outcomes.
See full Manual company page
